02 Mar MOBILion Selected as Healthcare Startup Finalist for PACT 2020 Enterprise Awards
Chadds Fords, PA. — MOBILion Systems, Inc. was selected as a finalist for the Philadelphia Alliance for Capital and Technologies (PACT) 2020 Enterprise Awards in the Healthcare Startup category. The Enterprise Awards are one of the Philadelphia region’s most prestigious business honors for technology and life sciences companies.
This nomination highlights MOBILion’s position as a leading healthcare startup in the region and arises as the company is ramping up for the launch of their first product. MOBILion is being recognized for successfully building a company to commercialize a best-in-class ion mobility separations technology, called Structures for Lossless Ion Manipulation (SLIM), which efficiently enhances the view of clinically important molecules to improve the characterization of protein-based therapeutics and accelerate diagnostic discoveries.
“We are honored that PACT is recognizing our accomplishments toward commercializing a novel analytical technology that will ultimately help our pharmaceutical customers develop better, safer biologic therapeutics and enable clinical researchers and diagnostic labs to better diagnose and treat disease,” said Melissa Sherman, Chief Executive Officer of MOBILion. “As a Philadelphia-based company, we are proud to contribute to the growth of this thriving life science corridor.”
To date, most classical analytical techniques are too slow, too complex and/or not powerful enough to address characterization challenges in biopharma drug development, early disease detection and clinical diagnostic markets. MOBILion is commercializing a ‘digital’ separations technology that combines maximum resolution, faster analysis time and simpler workflows to aide in development of safer, more effective therapeutics and more accurate diagnostics.
About MOBILion Systems, Inc.
MOBILion Systems is enabling advancements in disease diagnosis and treatment by commercializing instruments that improve multi-omic disease, drug, and biomarker discovery. Enhancing the study of the complement to genomics provides a better understanding of disease and drug target mechanisms and paves the way for earlier disease detection, more accurate diagnostics, improved treatment options for individual patients, and reduced healthcare costs. MOBILion’s instruments provide unprecedented speed and resolution, allowing rapid detection of clinically relevant molecules such as proteins, peptides, metabolites, glycans, lipids, etc., to accelerate biologic drug development and biomarker discovery. MOBILion’s instruments process population-scale samples in days vs. years and detect molecules never before seen with existing instrumentation, providing researchers and clinicians with the ability to better predict, diagnose and treat disease. The company is headquartered in Chadds Ford, Pennsylvania within the Philadelphia biopharmaceutical and medical innovation corridor.
MOBILion Media Contact
MOBILion Systems, Inc.